Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ: DSGN )

4.780 +0.420 (+9.63%)
Streaming Delayed Price Updated: 1:39 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Design Therapeutics, Inc. - Common Stock

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Investor Alert: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Design Therapeutics, Inc. 
Via SBWire
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 01/19/2023 -- Design Therapeutics, Inc. is under investigation over potential securities laws violations. 
Via SBWire
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 
From Design Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.